OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM(®), a self-assembling domain which improves a...

Descripción completa

Detalles Bibliográficos
Autores principales: Primard, Charlotte, Monchâtre-Leroy, Elodie, Del Campo, Judith, Valsesia, Séverine, Nikly, Elsa, Chevandier, Marion, Boué, Franck, Servat, Alexandre, Wasniewski, Marine, Picard-Meyer, Evelyne, Courant, Thomas, Collin, Nicolas, Salguero, Francisco J., Le Vert, Alexandre, Guyon-Gellin, Delphine, Nicolas, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319154/
https://www.ncbi.nlm.nih.gov/pubmed/37409116
http://dx.doi.org/10.3389/fimmu.2023.1188605
Descripción
Sumario:Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM(®), a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.

Ejemplares similares